UMIN ID: UMIN000015997
Registered date:20/12/2014
WT1 peptide-based cancer vaccine for long-term maintenance of anti-tumor immunity
Basic Information
Recruitment status | Complete: follow-up complete |
---|---|
Health condition(s) or Problem(s) studied | solid tumor, malignant lymphoma, acute leukemia |
Date of first enrollment | 2014/12/24 |
Target sample size | 56 |
Countries of recruitment | Japan |
Study type | Interventional |
Intervention(s) | Administration of WT1 peptide vaccine |
Outcome(s)
Primary Outcome | DTH to WT1 peptide Frequency of WT1 specific CTLs |
---|---|
Secondary Outcome | Safety 1 Numbers and frequencies of adverse effects defined in NCI-CTCAE v4.0 2 Frequencies of hematological- and non-hematological adverse effects which result in suspension or withdrawal of WT1 peptide vaccine Anti-tumor effects Anti-tumor effects are evaluated at 3-6 months intervals by the method described elsewhere. |
Key inclusion & exclusion criteria
Age minimum | 20years-old |
---|---|
Age maximum | 85years-old |
Gender | Male and Female |
Include criteria | |
Exclude criteria | 1. having severe infectious disease 2. having developed adverse effects (grade >=4) in the prior WT1 peptide vaccine trial 3. having severe complications 4. having severe mental disorders |
Related Information
Primary Sponsor | Osaka University Graduate Shool of Medicine, Functional Diagnostic Science |
---|---|
Secondary Sponsor | |
Source(s) of Monetary Support | MEXT(Japan),Non-pharmaceutical companies |
Secondary ID(s) |
Contact
public contact | |
Name | Yusuke Oji |
Address | 1-7 Yamada-oka Suita city Osaka, Japan Japan |
Telephone | 06-6879-2597 |
oji@sahs.med.osaka-u.ac.jp | |
Affiliation | Osaka University Graduate School of Medicine Cancer Stem Cell Biology |
scientific contact | |
Name | Haruo Sugiyama |
Address | 1-7 Yamada-oka Suita city Osaka, Japan Japan |
Telephone | 06-6879-2597 |
sugiyama@sahs.med.osaka-u.ac.jp | |
Affiliation | Osaka University Graduate School of Medicine Dept Functional Diagnostic Science |